These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16901062)

  • 1. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
    de Leeuw PW
    Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.
    Cooper WO
    J Cardiovasc Nurs; 2008; 23(1):20-4. PubMed ID: 18158502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major congenital malformations after first-trimester exposure to ACE inhibitors.
    Cooper WO; Hernandez-Diaz S; Arbogast PG; Dudley JA; Dyer S; Gideon PS; Hall K; Ray WA
    N Engl J Med; 2006 Jun; 354(23):2443-51. PubMed ID: 16760444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
    de Jong-van den Berg LT; Bakker MK; de Walle HE; van den Berg PB
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2222-3. PubMed ID: 17061436
    [No Abstract]   [Full Text] [Related]  

  • 5. ACE inhibitors and birth defects.
    Prescrire Int; 2006 Dec; 15(86):223. PubMed ID: 17167930
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
    Schaefer C
    Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
    Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACE inhibitors and congenital anomalies.
    Friedman JM
    N Engl J Med; 2006 Jun; 354(23):2498-500. PubMed ID: 16760451
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations].
    Lonati C; Morganti A
    Pediatr Med Chir; 2009; 31(3):137-9. PubMed ID: 19739495
    [No Abstract]   [Full Text] [Related]  

  • 10. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
    Quan A
    Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE inhibitors and major congenital malformations.
    Scialli AR; Lione A
    N Engl J Med; 2006 Sep; 355(12):1280; author reply 1281. PubMed ID: 16998965
    [No Abstract]   [Full Text] [Related]  

  • 12. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Mar; 46(11):240-2. PubMed ID: 9082178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient use of cardiovascular drugs during pregnancy.
    Andrade SE; Raebel MA; Brown J; Lane K; Livingston J; Boudreau D; Rolnick SJ; Roblin D; Smith DH; Dal Pan GJ; Scott PE; Platt R
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):240-7. PubMed ID: 18200619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists].
    Sørensen AM; Christensen S; Jonassen TE; Andersen D; Petersen JS
    Ugeskr Laeger; 1998 Mar; 160(10):1460-4. PubMed ID: 9520613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibitors and major congenital malformations.
    Sealey JE; Itskovitz-Eldor J
    N Engl J Med; 2006 Sep; 355(12):1280-1; author reply 1281. PubMed ID: 16990393
    [No Abstract]   [Full Text] [Related]  

  • 16. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.
    Piper JM; Ray WA; Rosa FW
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):429-32. PubMed ID: 1495700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
    Walfisch A; Al-maawali A; Moretti ME; Nickel C; Koren G
    J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin converting enzyme inhibitors in pregnancy.
    Mastrobattista JM
    Semin Perinatol; 1997 Apr; 21(2):124-34. PubMed ID: 9201818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.
    Tabacova S; Little R; Tsong Y; Vega A; Kimmel CA
    Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):633-46. PubMed ID: 14762979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy.
    Bowen ME; Ray WA; Arbogast PG; Ding H; Cooper WO
    Am J Obstet Gynecol; 2008 Mar; 198(3):291.e1-5. PubMed ID: 18191803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.